Key result
Melatonin supplementation improves arterial stiffness at 1 year in patients with essential hypertension.
Why the study?
Oxidative stress and chronic inflammation are implicated in endothelial damage and vascular stiffness in hypertension, prompting evaluation of physiological antioxidant supplementation.
Does melatonin supplementation improve arterial stiffness and oxidative stress in patients with essential hypertension?
RCT (n=23)
Open-label
1:1
No
Does melatonin supplementation improve arterial stiffness and oxidative stress in patients with essential hypertension?
p-value: p=0.022
Long-term, low-dose melatonin supplementation may improve arterial stiffness and oxidative balance in patients with essential hypertension.
May support low-dose melatonin as adjunct for arterial stiffness in hypertension; extends RCT evidence on oxidative stress-vascular links.
Among cardiovascular diseases, hypertension is one of the main risk factors predisposing to fatal complications. Oxidative stress and chronic inflammation have been identified as potentially responsible for the development of endothelial damage and vascular stiffness, two of the primum movens of hypertension and cardiovascular diseases. Based on these data, we conducted an open-label randomized study, first, to evaluate the endothelial damage and vascular stiffness in hypertense patients; second, to test the effect of supplementation with a physiological antioxidant (melatonin 1 mg/day for 1 year) in patients with essential hypertension vs. hypertensive controls. Twenty-three patients of either gender were enrolled and randomized 1:1 in two groups (control and supplemented group). The plasmatic total antioxidant capacity (as a marker of oxidative stress), blood pressure, arterial stiffness, and peripheral endothelial function were evaluated at the beginning of the study and after 1 year in both groups. Our results showed that arterial stiffness improved significantly (p = 0.022) in supplemented patients. The endothelial function increased too, even if not significantly (p = 0.688), after 1 year of melatonin administration. Moreover, the supplemented group showed a significative reduction in TAC levels (p = 0.041) correlated with the improvement of arterial stiffness. These data suggest that melatonin may play an important role in reducing the serum levels of TAC and, consequently, in improving arterial stiffness.
No takes yet. Share an insight, caveat, or question.
Franco et al. (2022) conducted an RCT in Essential hypertension (n=23). Melatonin vs. Antihypertensive therapy alone was evaluated on Arterial stiffness (p=0.022). Melatonin supplementation at 1 mg/day for 1 year significantly improved arterial stiffness (p=0.022) and reduced total antioxidant capacity levels in patients with essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: